

Dr Andrew Kelly – Executive Director, Bio Pacific Partners

Dr Andrew Kelly has a forty-year career in science and science commercialisation spanning health, food & agriculture. Dr Kelly was the co-founder of BioPacific Ventures, a \$100 million life sciences specialist venture capital fund that operated in both New Zealand and Australia. More recently he co-founded BioPacific Partners which has built a centre of expertise in bridging local innovations into international markets via global health, food & agriculture companies.

Dr Kelly has deep experience in corporate governance including previous appointments as a Director of Horizon Science, Focus Genetics, Anzamine, Cleveland Biosensors, Wool Equities (NZX:WEL) and both BioPacific entities. He was also a member of the board of San Diego based CoDA Therapeutics Inc. Dr Kelly has also been a member of several significant committees including the KiwiNet Investment Committee, the Australian biotechnology organisation's National Committee on Food & Agtech and the New Zealand biotech association's National Advisory Committee. Last year he was given the Lifetime Achievement Award by NZBIO.

Starting with a Bachelor of Veterinary Science degree in the late 1970s, Andrew engaged in life science R&D in Australia & Canada, including Masters (1982-1984) and PhD (1988-1992) degrees in veterinary epidemiology from the Universities of Saskatchewan and Melbourne. He has 28 peer-reviewed scientific publications. He then led three separate research institutes – the Pastoral & Veterinary Institute (1992-1996), the Institute of Sustainable Agriculture (1997) and Invermay Research Centre (1998-2002). In the early 2000s Andrew led Product Development and Investment for AgResearch, New Zealand including deep engagement with start-ups and fund-raising.

